.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Chubb
Julphar
Express Scripts
Teva
US Department of Justice
Queensland Health
AstraZeneca
Chinese Patent Office
Fuji

Generated: September 24, 2017

DrugPatentWatch Database Preview

Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride and what is the scope of dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride patent protection?

Dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride.

Summary for Generic Name: dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

Tradenames:1
Patents:0
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Clinical Trials: see list6,535
Drug Prices:see low prices
DailyMed Link:dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-002Nov 30, 1984► Subscribe► Subscribe
Novartis
EMBOLEX
dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride
INJECTABLE;INJECTION018885-001Nov 30, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Farmers Insurance
Covington
Colorcon
Argus Health
Medtronic
Accenture
McKesson
US Army
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot